
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Asthma Therapeutics Market**

According to Intelli, the U.S. Asthma Therapeutics Market size was valued at USD 10,717.3 Million in 2024 and is projected to reach USD 14,780.16 Million by 2032, growing at a CAGR of 4.52% from 2025 to 2032.



Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, shortness of breath, chest tightness, and persistent coughing. It affects people of all ages and can range from mild to severe, with symptoms often triggered by allergens, cold air, exercise, or respiratory infections. The risk factors for developing asthma are closely linked to both genetic and environmental influences. A family history of asthma or allergies significantly increases the likelihood of developing the condition, suggesting a strong hereditary component. Environmental exposures also play a critical role, regular exposure to tobacco smoke, whether during pregnancy, childhood, or adulthood, can irritate and damage the lungs, increasing asthma risk. Air pollution, including smog and particulate matter, can inflame the airways and trigger asthma symptoms, especially in urban areas. Additionally, certain occupational environments that involve exposure to chemicals, dust, or fumes such as in construction, farming, or manufacturing can lead to the development of asthma in adults. While asthma has no permanent cure, it can be effectively controlled with the right treatment and care. Management typically involves the use of medications such as inhaled corticosteroids to reduce long-term airway inflammation, and bronchodilators to provide quick relief during flare-ups. In addition to medication, lifestyle changes play a crucial role—these include identifying and avoiding asthma triggers, maintaining a clean and healthy living environment, and adhering to a personalized asthma action plan. Early detection and consistent management are essential to minimize symptoms, prevent severe attacks, and enhance overall quality of life.

**U.S. Asthma Therapeutics Market Definition**

The U.S. asthma therapeutics market refers to the segment of the healthcare industry focused on the research, development, production, and distribution of drugs and therapies designed to treat and manage asthma. The market includes a diverse array of pharmaceutical products aimed at managing asthma symptoms and improving patient outcomes. These products range from quick-relief medications, such as short-acting beta agonists used during asthma attacks, to long-term control therapies like inhaled A close-up of hands holding a tablet and a pen

Description automatically generatedcorticosteroids and leukotriene modifiers that help prevent symptoms. Additionally, the market features advanced biologic therapies, targeted monoclonal antibodies designed for patients with severe or treatment-resistant asthma as well as combination treatments that enhance effectiveness and convenience. Beyond medications, the market also encompasses essential healthcare services, including diagnostic tools, structured disease management programs, and educational resources to support patient awareness and adherence to treatment plans.

**U.S. Asthma Therapeutics Market Overview**

The U.S. asthma therapeutics market is driven by several key factors that contribute to its continued growth and evolution. One of the primary drivers is the rising prevalence of asthma across all age groups, fueled by environmental factors such as air pollution, urbanization, and exposure to allergens and irritants. In addition, advancements in drug development are significantly reshaping the U.S. asthma therapeutics market, with a notable shift toward biologics and personalized medicine. Biologic therapies such as monoclonal antibodies like omalizumab, mepolizumab, and dupilumab, are designed to target specific immune pathways involved in asthma, making them particularly effective for patients with severe, treatment-resistant, or eosinophilic asthma phenotypes. These therapies mark a departure from the one-size-fits-all approach, offering more precise, individualized treatment options that can significantly reduce exacerbations, improve lung function, and enhance overall quality of life. Personalized medicine, which involves tailoring treatment based on a patient’s genetic makeup, biomarkers, and disease subtype, is becoming increasingly important in guiding therapeutic decisions. Moreover, improvements in inhaler technologies and drug delivery systems enhance treatment adherence and patient outcomes. The growing elderly population, who are more susceptible to chronic respiratory conditions, further boosts demand for long-term asthma care. Robust research and development (R&D) investments by pharmaceutical companies are playing a crucial role in driving innovation within the U.S. asthma therapeutics market. These investments are leading to the discovery and commercialization of advanced treatment options. At the same time, favorable reimbursement policies and insurance coverage are enhancing patient access to these high-cost therapies, particularly for those with severe or chronic forms of asthma. This combination of scientific progress and financial accessibility is accelerating the adoption of innovative treatments and fostering sustained market growth.

A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Asthma Therapeutics Market Segmentation**

The U.S. asthma therapeutics market can be segmented based on several factors, including drug type, route of administration, and distribution channel.

**U.S. Asthma Therapeutics Market, By Drug Type**

* **Quick-Relief Medications**
* **Long-Term Control Medications**
* **Biologics**
* **Combination Therapies**

In the U.S. asthma therapeutics market, quick-relief medications hold a significant market share due to their widespread use for immediate symptom relief during asthma attacks. Short-acting beta agonists (SABAs) like albuterol are commonly prescribed and are essential in acute management. However, long-term control medications, particularly inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs), dominate the market in terms of volume, as they are crucial for managing asthma over time and preventing exacerbations. The biologics segment, though smaller in comparison, is experiencing rapid growth due to their effectiveness in treating severe asthma cases, especially among patients who do not respond to conventional therapies. Biologics offer targeted, personalized treatment, which has driven their adoption. Combination therapies, which combine long-term control and quick-relief medications, are gaining popularity for their convenience and enhanced patient adherence, contributing to a growing share in the market.

**U.S. Asthma Therapeutics Market, By Route of Administration**

* **Inhalation**
* **Oral**
* **Injectable**

The inhalation route of administration dominates the U.S. asthma therapeutics market, as it is the most effective and direct method for delivering medications directly to the lungs. Inhalers whether metered-dose inhalers (MDIs), dry powder inhalers (DPIs), or nebulizers, remain the primary choice for both quick-relief and long-term control medications, providing fast-acting and localized treatment for asthma symptoms. Although less dominant than inhalation therapies, the oral route remains an important component of the A close-up of hands holding a tablet and a pen

Description automatically generatedU.S. asthma therapeutics market. Oral medications, such as leukotriene receptor antagonists (LTRAs), provide a convenient and effective option for long-term asthma management, particularly for patients who struggle with proper inhaler technique or prefer a pill-based regimen. These treatments offer a non-invasive alternative that supports symptom control and enhances patient compliance, making them a valuable choice within the broader spectrum of asthma care options. The injectable segment, driven by the growing popularity of biologics, is rapidly gaining traction, particularly for severe asthma cases where targeted, immune-modulating therapies like monoclonal antibodies offer a transformative solution. Injectable biologics, administered via subcutaneous injection, are increasingly becoming the go-to option for patients with uncontrolled asthma, driving innovation and expansion in this segment.

**U.S. Asthma Therapeutics Market, By Distribution Channel**

* **Hospital Pharmacies**
* **Online Pharmacies**
* **Retail Pharmacies**

The U.S. asthma therapeutics market is segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies, each playing a vital role in ensuring access to essential medications. Hospital pharmacies serve as a key channel for patients requiring acute care or advanced treatments, such as biologics administered in clinical settings. Retail pharmacies hold a dominant share of the market due to their widespread presence and convenience, offering a broad range of prescription and over-the-counter asthma medications for day-to-day management. With growing digital adoption, online pharmacies are rapidly expanding, driven by consumer demand for convenience, home delivery, and competitive pricing. This channel is increasingly popular among chronic asthma patients who require regular medication refills, contributing to the evolving dynamics of drug distribution in the U.S.

**Key Players**

The “U.S. Asthma Therapeutics Market" study report will provide valuable insight emphasizing the U.S. market. The major players GlaxoSmithKline, AstraZeneca, Novartis AG, Sanofi, Teva Pharmaceuticals, Merck & Co., Inc., Pfizer Inc., Roche Holding AG, Regeneron Pharmaceuticals, AbbVie Inc., Amgen Inc., Johnson & Johnson, Viatris Inc., Cipla USA Inc., Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Vertex A close-up of hands holding a tablet and a pen

Description automatically generatedPharmaceuticals among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2025, GlaxoSmithKline’s investigational biologic, depemokimab, reached a key regulatory milestone with its acceptance for FDA review as an add-on treatment for patients with type 2 inflammatory asthma.
* In 2024, AstraZeneca’s biologic therapy, Fasenra (benralizumab) achieved FDA approval for pediatric use in children aged 6 to 11 years who have severe eosinophilic asthma. This expanded indication marks a critical advancement in pediatric asthma care, as it allows for earlier intervention in young patients whose asthma is driven by high levels of eosinophils, a type of white blood cell linked to inflammation in the airways.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Asthma Therapeutics Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Asthma Therapeutics Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. ASTHMA THERAPEUTICS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. ASTHMA THERAPEUTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. ASTHMA THERAPEUTICS MARKET, BY DRUG TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Quick-Relief Medications

5.3 Long-Term Control Medications

5.4 Biologics

5.5 Combination Therapies

**6 U.S. ASTHMA THERAPEUTICS MARKET, BY** **ROUTE OF ADMINISTRATION**

6.1 Overview

6.2 Inhalation

6.3 Oral

6.4 Injectable

**7 U.S. ASTHMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL**

7.1 Overview

7.2 Hospital Pharmacies

7.3 Online Pharmacies

7.4 Retail Pharmacies

1. **U.S. ASTHMA THERAPEUTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 GlaxoSmithKline**

* + 1. A close-up of hands holding a tablet and a pen

       Description automatically generatedOverview
    2. Financial Performance
    3. Product Outlook
    4. Key developments
  1. **AstraZeneca**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Novartis AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Sanofi**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Teva Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Merck & Co., Inc.**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  6. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Roche Holding AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Regeneron Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **AbbVie Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Amgen Inc.**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  4. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Viatris Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Cipla USA Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Glenmark Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Lupin Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  9. **Vertex Pharmaceuticals**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research